edaravone has been researched along with Diabetic Cardiomyopathies in 2 studies
Diabetic Cardiomyopathies: Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, L | 1 |
| Zeng, YQ | 1 |
| Gu, JH | 1 |
| Song, R | 1 |
| Cang, PH | 1 |
| Xu, YX | 1 |
| Shao, XX | 1 |
| Pu, LJ | 1 |
| Luo, HY | 1 |
| Zhou, XF | 1 |
| Ji, L | 1 |
| Liu, Y | 1 |
| Zhang, Y | 1 |
| Chang, W | 1 |
| Gong, J | 1 |
| Wei, S | 1 |
| Li, X | 1 |
| Qin, L | 1 |
2 other studies available for edaravone and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Novel oral edaravone attenuates diastolic dysfunction of diabetic cardiomyopathy by activating the Nrf2 signaling pathway.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Edaravone; NF-E2-Rel | 2022 |
The antioxidant edaravone prevents cardiac dysfunction by suppressing oxidative stress in type 1 diabetic rats and in high-glucose-induced injured H9c2 cardiomyoblasts.
Topics: Animals; Antioxidants; Antipyrine; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Prot | 2016 |